Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation

/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...

Related Keywords

Stockholm ,Sweden ,United States ,Jacob Milligan ,Eric Mcintyre ,Joana Ministro ,Deanna Nguyen ,Brandy Spencer ,Daniel Rios ,Joshua Friedman ,Hussam Shaheen ,Eric Zhu ,Rita Vaz ,Linkedin ,Spyre Therapeutics Inc ,Prnewswire Spyre Therapeutics Inc ,Company Or Spyre ,Paragon Therapeutics Inc ,Nasdaq ,Clinical Development Of Spyre ,Colitis Organisation ,Inflammatory Bowel Disease ,Paragon Therapeutics ,Annual Congress ,European Crohn ,Clinical Development ,Novel Monoclonal Antibody Drug Candidate ,Prolonged Half Life ,Spyre Therapeutics ,Quarterly Report ,Nc ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Surveys ,Olls And Research ,Trade Show News ,